🔗 Permalink

Inventor profile of:

Rob BURKE

City:

Encinitas, California

Country:

United States

Published Applications:

Last publication date:

2025-06-19

Top Assignees for applications by Rob BURKE

The entities that hold a legal rights for patent applications filed by inventor BURKE Rob:

AVIDITY BIOSCIENCES, INC. 18 La Jolla, CA United States
AVIDITY BIOSCIENCES, INC. 8 San Diego, CA United States
AVIDITY BIOSCIENCES LLC 2 La Jolla, CA United States
Merck Sharp Dohme Corp. 1 Rahway, NJ United States

Recent patent applications by BURKE Rob

Rob BURKE from Encinitas, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-06-19

US20250195676A1

Human necessities

COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY

#2 | 2025-05-29

US20250171544A1

Chemistry; metallurgy

NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF

#3 | 2025-05-29

US20250170260A1

Human necessities

NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING

#4 | 2025-05-22

US20250161344A1

Human necessities

NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING

#5 | 2025-05-15

US20250152726A1

Human necessities

NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF

#6 | 2024-10-31

US20240358736A1

Human necessities

NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING

#7 | 2023-12-14

US20230398231A1

Human necessities

COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY

#8 | 2023-06-29

US20230201363A1

Human necessities

Compositions and methods of treating muscle atrophy and myotonic dystrophy

#9 | 2023-06-29

US20230201362A1

Human necessities

Compositions and methods of treating muscle atrophy and myotonic dystrophy

#10 | 2023-02-16

US20230047754A1

Human necessities

COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY

#11 | 2022-12-29

US20220409735A1

Human necessities

Compositions and methods of treating muscle dystrophy

#12 | 2022-12-15

US20220395580A1

Human necessities

NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF

#13 | 2022-10-13

US20220324984A1

Chemistry; metallurgy

NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF

#14 | 2022-10-06

US20220313833A1

Human necessities

Nucleic acid-polypeptide compositions and methods of inducing exon skipping

#15 | 2022-06-21

US17364754

Human necessities

Nucleic acid-polypeptide compositions and uses thereof

#16 | 2022-05-05

US20220133900A1

Human necessities

Compositions and methods of treating muscle atrophy and myotonic dystrophy

#17 | 2022-04-26

US17463473

Human necessities

Nucleic acid-polypeptide compositions and methods of inducing exon skipping

#18 | 2022-03-31

US20220096647A1

Human necessities

COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY

#19 | 2022-03-10

US20220072145A1

Human necessities

Nucleic acid-polypeptide compositions and methods of inducing exon skipping

#20 | 2022-03-03

US20220062434A1

Human necessities

Compositions and methods of treating muscle atrophy and myotonic dystrophy

#21 | 2022-02-10

US20220040323A1

Human necessities

Compositions and methods of treating muscle atrophy and myotonic dystrophy

#22 | 2022-02-10

US20220040322A1

Human necessities

Compositions and methods of treating muscle atrophy and myotonic dystrophy

#23 | 2022-01-13

US20220008550A1

Human necessities

Compositions and methods of treating muscle atrophy and myotonic dystrophy

#24 | 2021-09-30

US20210299266A1

Human necessities

Compositions and methods of treating muscle dystrophy

#25 | 2021-06-24

US20210187116A1

Human necessities

Compositions and methods of treating muscle atrophy and myotonic dystrophy

#26 | 2021-06-17

US20210179720A1

Chemistry; metallurgy

Nucleic acid-polypeptide compositions and uses thereof

#27 | 2021-05-27

US20210155662A1

Chemistry; metallurgy

MYC NUCLEIC ACIDS AND USES THEREOF

#28 | 2020-12-31

US20200405877A1

Human necessities

Compositions and methods of treating muscle atrophy and myotonic dystrophy

#29 | 2020-09-10

US20200282074A1

Human necessities

NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING

#30 | 2020-04-23

US20200123261A1

Chemistry; metallurgy

NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF

#31 | 2019-10-03

US20190298847A1

Human necessities

Compositions and methods of treating muscle atrophy and myotonic dystrophy

#32 | 2019-06-27

US20190192681A1

Human necessities

Nucleic acid-polypeptide compositions and uses thereof

#33 | 2019-02-28

US20190062437A1

Chemistry; metallurgy

Nucleic acid-polypeptide compositions and uses thereof

#34 | 2019-02-28

US20190062436A1

Chemistry; metallurgy

Nucleic acid-polypeptide compositions and uses thereof

#35 | 2019-02-28

US20190062435A1

Chemistry; metallurgy

NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF

#36 | 2019-01-17

US20190015442A1

Human necessities

Dual molecular delivery of oligonucleotides and peptide containing conjugates

#37 | 2019-01-03

US20190000987A1

Human necessities

Nucleic acid-polypeptide compositions and uses thereof

#38 | 2019-01-03

US20190000986A1

Human necessities

Nucleic acid-polypeptide compositions and methods of inducing exon skipping

#39 | 2018-12-27

US20180371102A1

Chemistry; metallurgy

Nucleic acid-polypeptide compositions and uses thereof

#40 | 2018-12-27

US20180369400A1

Human necessities

Nucleic acid-polypeptide compositions and methods of inducing exon skipping

#41 | 2017-11-02

US20170314030A1

Chemistry; metallurgy

Beta-catenin nucleic acids and uses thereof

#42 | 2017-10-05

US20170283476A1

Chemistry; metallurgy

MYC NUCLEIC ACIDS AND USES THEREOF

#43 | 2017-10-05

US20170281795A1

Human necessities

NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF

InventorID:

1999589 ⎘